AivoCode receives a $2.5M SBIR grant to develop a novel neurotherapeutic peptide for TBI

AivoCode, Inc., a neuroscience-focused company committed to advancing therapeutics to address dire unmet medical needs, announces today that the company has been awarded a Direct-to Phase II Small Business Innovative Research (SBIR) grant valued at $2,500,000 from the National Institute of Health. This award will support the development of AC01 peptide for treatment of traumatic brain injury.

Preliminary testing of AC01 demonstrates the therapeutic potential of the treatment approach to improve the recovery following TBI, which is a major clinical problem due to the high incidence and the severity of the subsequent sequelae.

“We are grateful for NIH’s recognition of the breakthrough potential of this project and are excited to see years of strong interdisciplinary research efforts come to fruition,” said Aman Mann, PhD, Co-founder, and Chief Executive Officer of AivoCode.